title: Corneal and conjunctival sensitivity changes following intravitreal ranibizumab injection in diabetic retinopathy.
abstract: OBJECTIVE
  To evaluate corneal and conjunctival sensitivity changes following intravitreal ranibizumab (IVR) injection in eyes with diabetic retinopathy.
  
  
  METHODS
  Forty-six eyes of 46 patients with diabetic macular edema who underwent intravitreal injection of ranibizumab were included in this prospective study. Fifty eyes of 50 type 2 diabetes mellitus patients served as controls. Each participant underwent a complete ophthalmological examination. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. IVR (0.5 mg/0.05 mL) was injected from the lower temporal quadrant. Corneal and conjunctival sensitivities were measured using the Cochet-Bonnet esthesiometer.
  
  
  RESULTS
  Corneal sensitivity (CS) increased significantly on the first day in temporal and nasal corneas in treated eyes (P=0.005 and P=0.000, respectively). At week one the increase continued and the difference was significant in central, temporal, and nasal corneas (all P=0.000). In fellow eyes, CS increased significantly only in nasal cornea (P=0.004). Only nasal conjunctival sensitivity increased significantly both in treated and fellow eyes at week one (P=0.000 and P=0.005, respectively).
  
  
  CONCLUSIONS
  IVR may have a potential to increase corneal and conjunctival sensitivities in diabetic retinopathy.
authors.affiliation: Department of Ophthalmology, Kırıkkale University School of Medicine , Kırıkkale, Turkey .
authors.forename: Nurgül
authors.initials: N
authors.lastname: Örnek
authors.forename: Kemal
authors.initials: K
authors.lastname: Örnek
authors.forename: İnci Elif
authors.initials: İE
authors.lastname: Erbahçeci
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D016022:Case-Control Studies; D003228:Conjunctiva / Q000187:drug effects* / Q000503:physiopathology; D003315:Cornea / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab